Influenza is a major public health concern. Vaccination is the most effective and economic approach for stopping influenza virus transmission, preventing infections, and reducing the severity of associated complications. Annual influenza vaccination has been recommended for persons aged ≥6 months in the United States since 2010 [1] . However, considerable variation in vaccine effectiveness (VE) has been reported for different flu seasons, especially reduced VE against recent A/H3N2 viruses [2] [3] [4] [5] [6] [7] .
The performance of influenza vaccines depends predominantly on how well vaccine strains match with circulating viruses. Influenza hemagglutinin (HA) is the primary target of vaccination and its antigenicity varies considerably between different strains. Thus, vaccine strains used for manufacturing seasonal influenza vaccines must be evaluated and updated annually. In the vaccine strain evaluation process, standard reference ferret antisera play the determinant role in the final selection of vaccine strains; these antisera are raised by infecting influenza-seronegative ferrets with reference viruses representing recent and emergent isolates [8, 9] . Despite tremendous efforts by World Health Organization (WHO) collaborative centers, a mismatched vaccine strain sometimes is unavoidable and results in poor vaccine performance, as seen with the 2014-2015 Northern Hemisphere influenza vaccines [2, 9, 10] .
Such mismatches are at least partially attributed to the fact that standard reference ferret antisera and human postvaccination sera "see" emerging H3 variants differently [9, 11] . One key difference is that the immunity of ferrets used in the influenza vaccine selection process reflects exposure to either current vaccine virus or a representative emergent variant, but human immunity reflects and is greatly influenced by previous influenza infections and/or vaccinations [9, 12, 13] .
During this and the past century, humans have been exposed to a variety of influenza viruses. After the 1918 "Spanish flu" pandemic, A/H1N1 virus prevailed in the environment for almost 40 years until its disappearance in 1957, when the A/ H2N2 "Asian flu" pandemic began [14] . In 1968, a novel H3N2 virus derived from reassortment between human H2N2 virus and an avian H3 virus emerged, resulting in "Hong Kong flu" pandemic, which continues to circulate in an endemic pattern [14] . In 1977, 20 years since its last appearance, H1N1 virus from the 1918 lineage reemerged and began to co-circulate with H3N2 and type B virus in the environment [14] . And in 2009, a novel H1N1 virus, a descendant of the 1918 linage, caused the "swine flu" pandemic [14] . Thus, it is conceivable that the influenza antibody repertoire in children born after 2009 would be very distinct from that in older persons who have different exposure histories.
In addition, prior influenza vaccination also can shape preexisting immunity by inducing cross-reactive antibodies against antigenic variant viruses [15] [16] [17] [18] [19] . Lower VE in individuals with repeated annual vaccination compared with those not vaccinated in previous season has been reported, suggesting that residual protection from prior vaccination may interfere with the performance of current vaccines [3, 6, 7, [19] [20] [21] [22] . In this study, we assessed H3 cross-reactivity of seasonal influenza vaccines and elucidated the effects of age and prior influenza exposures on vaccination-induced human cross-reactive hemagglutination inhibition (HAI) antibodies by antigenic mapping.
METHODS

Human Postvaccination Sera
Archived human pre-and postvaccination sera were provided by government, industry, and international partners. All human samples were analyzed anonymously at the Center for Biologics Evaluation and Research, US Food and Drug Administration, in support of WHO annual influenza vaccine strain selection, which is considered to be a public health, nonresearch, regulatory activity that is exempt from human subjects review. Under institutional review board approval by individual participating institutes and with written informed consent, serum samples were collected from healthy persons in 3 age groups: children (6-36 months of age), younger adults (18-64 years of age), and older adults (≥65 years of age). Persons in each age group had been immunized with egg-based inactivated, non- 
HAI Assay and Data Analysis
Sera were pretreated with receptor-destroying enzyme (DenkaSeiken) and serially 2-fold diluted from the initial 1:10 dilution. Viruses were adjusted to 8 HA units/50 µL in phosphate-buffered saline. The HAI assays were performed, using 0.5% turkey red blood cells (RBCs) for H1N1 and type B viruses and 0.75%-1.00% guinea pig RBCs for H3N2 viruses, according to previously described procedures [9, 16, 17] . RBC agglutination was difficult with the most recent H3N2 isolates (eg, WI/20c) [23] ; thus, the H3N2-specific HAI assays for the 2015-2016 season were performed in the presence of 20 nM oseltamivir, as recommended by the WHO vaccine strain selection workgroup, unless otherwise specified. HAI titers were expressed as the reciprocal of the highest serum dilution that resulted in complete HAI. A titer of 5 was assigned if no inhibition was observed at the starting 1:10 serum dilution.
Geometric mean titers (GMTs) for prevaccination and postvaccination HAI titers were determined. Calculations were also made for seroprotection rates (% with postvaccination HAI titer of ≥40) and seroconversion rates (% with 4-fold increase in postvaccination HAI titer with either a prevaccination HAI titer of ≤1:10 and a postvaccination HAI titer of ≥1:40 or a prevaccination HAI titer of >1:10 and a minimum 4-fold rise in postvaccination HAI antibody titer).
Antigenic Map Construction
To minimize the biases caused by low reactor values (HAI titer ≤1:10), low-rank matrix completion was conducted before generating the antigenic maps (http://sysbio.cvm.msstate.edu/ AntigenMap) [24, 25] . Each HAI titer is normalized by the overall maximum value max(H ij ) and the maximum value for each column max(H j ), and the normalized value will be transformed into
A 2-dimensional map with multidimensional scaling was used to display antigenic distances between H3 viruses characterized [9] . Each gridline (horizontal and vertical) in the map is one antigenic unit distance corresponding to a 2-fold difference in HAI titers.
Pearson product-moment correlation coefficient was adopted as the correlation coefficient for any 2 sets of antigenic distances derived from antigenic cartography generated by HAI data: Bootstrap analyses were performed to minimize potential biases from small sample sizes by randomly selecting 100 sub-HAI tables from a corresponding parent table to calculate antigenic distances, and determine the correlation coefficients.
Statistical Analysis P < .05, determined by 2-way analysis of variance using Prism 6.02 software (GraphPad), was considered statistically significant. that the antibodies induced by the SWZ/13e vaccine component of 2015-2016 QIV might be inefficient in neutralizing newly emergent 3C.2a variants [9, 26, 27] .
RESULTS AND DISCUSSION
Age
The postvaccination H3 HAI titers for study participants who had a prevaccination HAI titer of <40 against the H1N1 and type B vaccine prototype viruses of 2015-2016 QIV were used to construct age-specific antigenic maps (Figure 2A-C) and calculate antigenic distances relative to SWZ/13e, respectively ( Figure 2D ). Regardless of the participants' ages, the new 3C.2a variants WI/20c and MI/15c were distant from SWZ/13e; however, the 2016-2017 H3 vaccine prototype virus HK/4801e (3C.2a) was close to SWZ/13e (Figure 2A-D) . For the 5 H3 strains characterized, antigenic distances determined using postvaccination sera from children correlated poorly with those determined using sera from younger adults ( Figure 2E ). In contrast, the antigenic distances of the same H3 strains determined using postvaccination sera from younger and older adults were highly correlated ( Figure 2E ). This age-specific difference in antigenic characterization can probably be explained by the fact that young children do not have the complex influenza exposure histories that adults have. This difference in exposure histories is especially true for persons born before 1957; this population of adults experienced all 3 pandemics in recent human history, the 1957-1958 H2N2 "Asian flu, " the 1968 H3N2 "Hong Kong flu, " and the 2009 H1N1 "swine flu" pandemics [14] .
Effect of Prior H1 or Type B Virus Exposure on Antigenic Characterization Derived From Human Postvaccination Sera
Because exposure history may contribute to age-specific differences in H3 antigenic characterization, we were curious whether previous H1 or type B virus exposure had an equal effect on antigenic distances of the H3 viruses characterized. All younger and older adults of the 2015-2016 QIV trial were combined into one group because of the high correlation between the antigenic maps derived from their postvaccination sera, and were then divided according to their paired prevaccination HAI titers against H1N1 and type B vaccine prototype viruses, as follows: (1) no H1/B-priming (prevaccination HAI titer of <40 against H1N1 and type B virus), (2) H1-priming (prevaccination HAI titer of ≥40 against H1N1 but of <40 against type B virus), and (3) B-priming (prevaccination HAI titer of ≥40 against type B but of <40 against H1N1 virus). Because all human sera analyzed were from archived samples with no infections/vaccinations documented, we used seroprotective HAI titer of ≥40 before vaccination to define previous exposures [9, 16, 17] . H3-specific postvaccination responses in participants with H1-priming differed from those with no H1/B-priming or B-priming only ( Figure 3A) . Specifically, H1-priming participants showed no reduction in postvaccination GMTs against HK/4801e compared with participants with no H1/B-priming or B-priming who had a 29%-38% GMT reduction ( Figure 3A) . In addition, H1-priming participants showed more GMT reduction against newly emergent WI/20c, but less GMT reduction against early isolated MI/15c (54%) than participants with no H1/B-priming or B-priming ( Figure 3A) . Accordingly, postvaccination HAI titer-derived H3 antigenic distances differed for participants in the 3 subgroups: WI/20c showed a longer distance to SWZ/13e in the map derived from H1-priming sera than those derived from no H1/B-priming or B-priming sera (Table 1 and Supplementary Figure 1A-C) . On the other hand, MI/15c showed a much shorter distance to SWZ/13e in the map derived from H1-priming sera than those derived from no H1/B-priming or B-priming sera (Table 1 and Supplementary Figure 1A-C) . The correlation coefficient analysis revealed that the H3 antigenic distances derived from no H1/B-priming sera correlated well with those derived from B-priming sera, but had a poor correlation with those derived from H1-priming sera (Table 1) . To minimize the bias e Bootstrap analyses, which were performed to minimize the potential biases from small sample sizes, randomly selected 100 sub-HAI tables from a corresponding parent table to calculate the correlation coefficient values ± SEMs on the H3 antigenic distances derived. potentially associated with the small sample size, the bootstrap analyses were conducted and indicated that the H3 antigenic distances derived from B-priming sera correlated significantly better than those derived from H1-priming sera ( [2, 9, 10, 28] . The participants with no H1/B-priming or B-priming had less GMT reduction against egg-grown SWZ/13e, but greater GMT reduction against cellgrown TX/50c than H1-priming participants ( Figure 3B ). Cellgrown TX/50c is antigenically different from its egg-grown counterpart, TX/50e, due to egg-adapted mutations at G186V and S219F in H3 antibody binding sites B and D [4, 9, 29] . However, the distance between TX/50c and TX/50e was much shorter in the map derived from H1-priming sera than those derived from no H1/B-priming and B-priming sera (Table 1 and Supplementary Figure 1E-G) . Additionally, TX/50c appeared much closer to SWZ/13e in the map derived from H1-priming sera than those derived from no H1/B-priming and B-priming sera (Supplementary Figure 1E-G) . These results suggested that H1-priming sera from the 2014-2015 QIV trial "see" TX/50c (3C.1) and SWZ/13e (3C.3a) as antigenically related, whereas no H1/B-priming and B-priming sera "see" these 2 strains as antigenically distinct. The antigenic distances determined with B-priming sera correlated obviously better with those determined with no H1/B-priming sera than those determined with H1-priming sera (Table 1) . This result was similar to that observed in the 2015-2016 QIV trial (Table 1) .
For the 2012-2013 TIV trial, all 3 participant groups had >50% reduction in postvaccination GMTs against the 4 representative circulating viruses, including TX/50c, which is in the same clade as VIC/361e (3C.1), the H3 vaccine prototype virus of 2012-2013 Northern Hemisphere TIV ( Figure 3C ). This reduction occurred because IVR-165, the actual vaccine reassortant used for 2012-2013 vaccine production, has gained 1 additional egg-adapted mutation (H156Q), which, in addition to mutations G186V and S219Y in VIC/361e, changed its original antigenicity and consequently caused it to become distinct from VIC/361e [4, 9, 29] . Thus, it is not surprising that 2012-2013 postvaccination sera responded poorly to the representative H3N2 variants, even though the original vaccine prototype virus, VIC/361e, matched most circulating H3N2 strains during the 2012-2013 season [4] . The antigenic distance between TX/50c and VIC/361e as determined using H1-priming sera was much shorter than that determined using no H1/B-priming sera or B-priming sera ( Table 1 ). The antigenic maps derived from 2012-2013 no H1/B-priming sera and B-priming sera were highly correlated with each other; whereas the antigenic distances determined with 2012-2013 H1-priming sera showed less though good correlation with those determined with no H1/B-priming sera (Table 1) . This trend was consistent with those observed during 2015-2016 and 2014-2015 vaccine trials.
Preexisting immunity can promote host resistance through cross-reactive antibodies against emerging viruses, the benefits of which have been well documented for the 2009 H1N1 pandemic [13, 16, 17, [30] [31] [32] [33] [34] . Prior H1N1 or H3N2 infection was also found to significantly augment HAI responses in laboratory animals to subsequent immunization of inactivated heterosubtypic vaccines, and the minimum dose required to induce detectable HAI titers was significantly reduced in hamsters with prior heterosubtypic infections compared with naive animals [35] . On the other hand, preexisting immunity can also potentially interfere with influenza vaccination due to "original antigenic sin, " a phenomenon by which immune memory is recalled to cross-react with historically related viruses rather than current vaccine strains [3, [36] [37] [38] . Postvaccination response has been reported to be inversely associated with the number of prior influenza vaccination, and reduced VE has been observed in patients with repeated annual vaccination [3, 7, [20] [21] [22] .
The average antigenic distances of H3 variants determined using no H1/B-priming sera, H1-priming sera, or B-priming sera were essentially identical during each influenza season, although the averages decreased over time (Table 1) . However, individual antigenic distances determined with H1-priming sera vs no H1/B-priming sera became considerably less correlated over the period studied, but B-priming groups remained highly correlated with no H1/B-priming groups across the seasons ( Figure 3D ). This finding suggests that the antigenic differences among H3 variants "seen" by H1-priming sera went in different directions from those "seen" by no H1/B-priming sera or B-priming sera. . The H3 antigenic maps derived from postvaccination sera of these H1/Bris-priming participants became less correlated with those derived from no H1/B-priming sera over time, following a similar trend to those determined using H1-priming sera (Table 1) . These results suggest that H1 virus preexposure could influence the H3-specific postvaccination response more than type B virus preexposure, which could be due to the fact that H1 virus generally causes more severe illness, thus having a greater effect on the immune system [39] . Apparently the longer CA/07-like virus is in circulation, the bigger the effect.
CONCLUSIONS
Our results indicate that human immunity to influenza virus is shaped significantly by exposure history, the complexity of which cannot be duplicated by standard reference ferret antisera with single virus infection [9, 12, 13] . Attention should be given to prior influenza infection/vaccination history of volunteers whose postvaccination sera are used for annual vaccine strain selection. Our study also highlights the need to investigate the impact of prior exposure, especially repeated annual vaccination on influenza vaccine performance.
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